Home » Stocks » AERI

Aerie Pharmaceuticals, Inc. (AERI)

Stock Price: $12.41 USD -0.59 (-4.54%)
Updated November 30, 4:00 PM EST - Market closed
After-hours: $12.41 0.00 (-0.02%) Nov 30, 5:13 PM

Stock Price Chart

Key Info

Market Cap 580.97M
Revenue (ttm) 83.11M
Net Income (ttm) -192.03M
Shares Out 46.81M
EPS (ttm) -4.19
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 30
Last Price $12.41
Previous Close $13.00
Change ($) -0.59
Change (%) -4.54%
Day's Open 13.00
Day's Range 12.38 - 13.10
Day's Volume 515,372
52-Week Range 9.12 - 25.52

More Stats

Market Cap 580.97M
Enterprise Value 583.29M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 46.81M
Float n/a
EPS (basic) -4.18
EPS (diluted) -4.19
FCF / Share -2.58
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 6.17M
Short Ratio 6.82
Short % of Float n/a
Beta 0.71
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 6.99
PB Ratio 9.92
Revenue 83.11M
Operating Income -170.04M
Net Income -192.03M
Free Cash Flow -118.73M
Net Cash -2.32M
Net Cash / Share -0.05
Gross Margin 50.88%
Operating Margin -204.59%
Profit Margin -231.00%
FCF Margin -142.85%
ROA -25.13%
ROE -142.61%
ROIC -48.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (14)

Buy 11
Overweight 1
Hold 1
Underweight 1
Sell 0

Analyst Consensus: Buy

Price Target

(118.94% upside)
Current: $12.41
Target: 27.17
*Average 12-month price target from 12 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth189.02%--------
Gross Profit65.0623.54-------
Operating Income-187-210-146-96.87-75.09-48.13-31.15-14.98-12.97
Net Income-200-233-145-99.06-74.36-48.13-31.60-15.64-13.42
Shares Outstanding45.4341.6635.3229.1425.7824.094.960.950.93
Earnings Per Share-4.39-5.58-4.11-3.40-2.88-2.00-6.38-16.39-14.50
Operating Cash Flow-150-153-93.21-79.84-55.75-33.73-16.45-14.97-12.00
Capital Expenditures-9.96-31.31-15.97-5.08-3.28-0.18-0.06-0.05-0.05
Free Cash Flow-160-184-109-84.92-59.03-33.91-16.51-15.02-12.05
Cash & Equivalents30920325023413714069.652.9315.07
Total Debt206-124124123123-2.33-
Net Cash / Debt10320312611013.3317.0269.650.5915.07
Book Value16722813610518.7828.0466.98-63.92-48.70
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Aerie Pharmaceuticals, Inc.
Country United States
Employees 380
CEO Vicente J. Anido

Stock Information

Ticker Symbol AERI
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: AERI
IPO Date October 25, 2013


Aerie Pharmaceuticals, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, dry eye, retinal diseases, and other eye diseases. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension. The company is also developing AVX-012, a clinical-stage dry eye product candidate; and AR-1105 and AR-13503 sustained-release implants for treating retinal diseases. Aerie Pharmaceuticals, Inc. has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.